Corcept Therapeutics Inc (CORT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Corcept Therapeutics reported revenue of $761.4M, up 12.8% from $675.0M the year before. Net income was $99.7M (a 13.1% net margin), or $0.82 per diluted share. Gross margin was 98.3% and operating margin was 5.9%. Operating activities generated $142.0M of cash, leaving $141.8M of free cash flow. At fiscal year end, Corcept Therapeutics held $836.7M in total assets against $188.8M in total liabilities, including $120.5M of cash and equivalents.
Open the full interactive Corcept Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Corcept Therapeutics Key Stats
| Share Price | $117.80 |
|---|---|
| Market Cap | $13.95B |
| P/E Ratio | 143.7 |
| Revenue YoY Growth | +12.8% |
| 52-Week Range | $32.15 – $123.57 |
| Shares Outstanding | 105.4 million (basic, 2026 Q2) |
Corcept Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $353.9M | $366.0M | $401.9M | $482.4M | $675.0M | $761.4M |
| Cost of Goods Sold | $5.6M | $5.3M | $5.4M | $6.5M | $10.9M | $13.0M |
| Gross Profit | $348.3M | $360.7M | $396.5M | $475.9M | $664.2M | $748.4M |
| Operating Income | $128.2M | $124.5M | $112.6M | $107.3M | $137.0M | $44.8M |
| Pre-Tax Income | $131.6M | $125.0M | $116.2M | $124.6M | $161.5M | $66.5M |
| Income Tax | $25.6M | $12.5M | $14.8M | $18.4M | $20.3M | -$33.2M |
| Net Income | $106.0M | $112.5M | $101.4M | $106.1M | $141.2M | $99.7M |
| Diluted EPS | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
Corcept Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $207.6M | $202.1M | $164.9M | $256.1M |
| Net Income | $19.7M | $24.3M | -$31.8M | $43.0M |
| Diluted EPS | $0.16 | $0.20 | -$0.30 | $0.36 |
Corcept Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $76.2M | $77.6M | $66.3M | $135.6M | $127.7M | $120.5M |
| Current Assets | $478.5M | $266.5M | $499.3M | $458.6M | $471.6M | $485.5M |
| Total Assets | $571.7M | $423.8M | $583.4M | $621.5M | $840.6M | $836.7M |
| Current Liabilities | $47.5M | $47.5M | $72.5M | $104.5M | $140.8M | $166.1M |
| Total Liabilities | $48.4M | $48.0M | $81.6M | $114.8M | $161.0M | $188.8M |
| Shareholders' Equity | $523.3M | $375.8M | $501.8M | $506.7M | $679.6M | $647.8M |
Corcept Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $152.0M | $167.9M | $120.3M | $127.0M | $198.1M | $142.0M |
| Cash From Investing | -$119.3M | $136.1M | -$114.3M | $90.9M | -$177.6M | $69.8M |
| Cash From Financing | $12.2M | -$302.6M | -$17.3M | -$148.7M | -$28.3M | -$220.4M |
| Free Cash Flow | $150.7M | $167.4M | $119.9M | $126.9M | $195.9M | $141.8M |
Figures from Corcept Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Corcept Therapeutics financials page for every line item.
Corcept Therapeutics Company Profile
| Ticker | CORT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Redwood City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001088856 |
Frequently Asked Questions
What was Corcept Therapeutics' revenue in fiscal 2025?
Corcept Therapeutics (CORT) reported revenue of $761.4M for fiscal 2025.
What is Corcept Therapeutics' annual revenue history?
Corcept Therapeutics' annual revenue by fiscal year: 2020: $353.9M; 2021: $366.0M; 2022: $401.9M; 2023: $482.4M; 2024: $675.0M; 2025: $761.4M.
What was Corcept Therapeutics' net income in fiscal 2025?
Corcept Therapeutics reported net income of $99.7M for fiscal 2025.
What was Corcept Therapeutics' earnings per share (EPS) in fiscal 2025?
Corcept Therapeutics' diluted EPS was $0.82 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Corcept Therapeutics generate in fiscal 2025?
Corcept Therapeutics generated $141.8M of free cash flow in fiscal 2025.
What was Corcept Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Corcept Therapeutics reported revenue of $256.1M.
How many shares of Corcept Therapeutics are outstanding?
Corcept Therapeutics reported a weighted average of 105.4 million basic shares outstanding in 2026 Q2.
What is Corcept Therapeutics' market cap?
Based on its latest closing price, Corcept Therapeutics (CORT) has a market capitalization of about $13.95B.
When does Corcept Therapeutics' fiscal year end?
Corcept Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Corcept Therapeutics headquartered?
Corcept Therapeutics lists its business address in Redwood City, California in its SEC filings.